Calidi Biotherapeutics, Inc. 8-K

What Happened
Calidi Biotherapeutics, Inc. (CLDI) filed an 8-K reporting that on July 10, 2026 it signed a new lease with BP3‑SD4 5580 Morehouse Drive LLC for approximately 9,038 rentable sq ft (Suite 120) at 5580 Morehouse Drive, San Diego, CA. The New Lease has an initial 44‑month term scheduled to commence on October 1, 2026 and expire on May 31, 2030. The company also entered a Lease Termination Agreement dated July 10, 2026 to end its existing lease with an affiliate landlord. Calidi estimates the move will save about $1.1 million per year in rent and facility-related expenses.

Key Details

• New Lease signed July 10, 2026 with BP3‑SD4 5580 Morehouse Drive LLC for ~9,038 rentable sq ft (Suite 120).
• Initial term: 44 months (scheduled Oct 1, 2026 – May 31, 2030); one option to extend for 3 years at fair‑market rent (subject to conditions).
• Company must deliver an irrevocable letter of credit of $113,574.78 within 10 days of lease execution; the LC generally must remain in effect until at least 120 days after lease expiration and may be drawn by the landlord upon certain events. (The LC creates a direct financial obligation disclosed under Item 2.03.)
• New Landlord is an affiliate of the landlord under the company’s prior lease; the lease and termination agreement are filed as exhibits to the 8‑K.

Why It Matters
The transaction is material because it reduces the company’s expected annual rent and facility costs by roughly $1.1M, which can improve operating cash flow and free up capital for R&D or other uses. At the same time, Calidi assumes a new contractual commitment (the lease) and must secure a letter of credit (~$113.6k), which is a new direct financial obligation and could affect near‑term liquidity or liquidity planning. Investors should note the specific lease term dates, extension conditions, and the cash or bank collateral requirement tied to the letter of credit.